2-amino-3-phosphonopropionic acid has been researched along with Fra(X) Syndrome in 1 studies
2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3
2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, ZH | 1 |
| Yang, Q | 1 |
| Feng, B | 1 |
| Liu, SB | 1 |
| Zhang, N | 1 |
| Xing, JH | 1 |
| Li, XQ | 1 |
| Wu, YM | 1 |
| Gao, GD | 1 |
| Zhao, MG | 1 |
1 other study available for 2-amino-3-phosphonopropionic acid and Fra(X) Syndrome
| Article | Year |
|---|---|
Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome.
Topics: Alanine; Animals; Cells, Cultured; Disease Models, Animal; Fragile X Mental Retardation Protein; Fra | 2012 |